当前位置:首页 > 报告详情

Roche 20260111_jpm_finalf.pdf

上传人: 明**** 编号:1069811 2026-01-17 14页 817.76KB

1、This presentation contains certain forward-looking statements.These forward-looking statements may be identified by words such as believes,expects,anticipates,projects,intends,should,seeks,estimates,future or similar expressions or by discussion of,among other things,strategy,goals,plans or intentio

2、ns.Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation,among others:1 pricing and product initiatives of competitors;2 legislative and regulatory developments and economic conditions;3 delay or

3、inability in obtaining regulatory approvals or bringing products to market;4 fluctuations in currency exchange rates and general financial market conditions;5 uncertainties in the discovery,development or marketing of new products or new uses of existing products,including without limitation negativ

4、e results of clinical trials or research projects,unexpected side-effects of pipeline or marketed products;6 increased government pricing pressures;7 interruptions in production;8 loss of or inability to obtain adequate protection for intellectual property rights;9 litigation;10 loss of key executiv

5、es or other employees;and11 adverse publicity and news coverage.Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roches earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the his

6、torical published earnings or earnings per share of Roche.For marketed products discussed in this presentation,please see full prescribing information on our website All mentioned trademarks are legally protected.Roche:Delivering the next innovation cycleTeresa Graham|CEO Roche PharmaceuticalsJPM He

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **前瞻性声明风险**:实际结果可能因竞争、监管、经济等因素与预期存在重大差异,每股增长预测不代表未来业绩必然匹配历史水平。 2. **2026年核心战略**:通过商业卓越、关键产品上市及产品组合 rejuvenation(焕新)维持增长,当前在售产品组合预计支撑增长至2028年。 3. **关键产品管线**: - 17款重磅产品(如Phesgo、Ocrevus)保持强劲增长,2026年将推出Gazyva、giredestrant等新药。 - 管线中11款新分子实体(NMEs)处于临床阶段,60%研发及销售涉及合作。 4. **研发里程碑**:2026年预计提交3款NMEs上市申请,包括乳腺癌药物giredestrant及多发性硬化症药物fenebrutinib。 5. **肥胖领域布局**:承诺成为肥胖领域前三玩家,2026年推进5款NMEs的关键III期数据,目标2030年前上市19款潜在新药。
**罗氏2026亮点?** **新药有何突破?** **肥胖领域布局?**
客服
商务合作
小程序
服务号
折叠